With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise.
The biotechnology sector, as measured by the XBI ETF, is extending its recent gains, building on strong positive momentum from earlier in the week. This rally was initially sparked by highly positive clinical trial results for a cancer vaccine from Moderna and Merck, which sent the sector to post-pandemic highs. The current move appears to be sustained by continued investor optimism and a flow of positive company-specific news, rather than a single new catalyst today.